scholarly journals Primary Kaposi sarcoma of the glans: A rare case in an HIV‐negative patient

2020 ◽  
Vol 8 (7) ◽  
pp. 1134-1137
Author(s):  
Farnaz Araghi ◽  
Mohammadreza Tabary ◽  
Farahnaz Bidari‐Zerehpoosh ◽  
Zahra Asadi‐Kani ◽  
Reza M. Robati
2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Xiaoming Yu ◽  
Keji Miao ◽  
Changsheng Zhou ◽  
Yuelin Cai ◽  
Xiaoying Huang ◽  
...  

Author(s):  
Aline Fernanda Cruz ◽  
José Augusto Dias Araújo ◽  
Samuel Macedo Costa ◽  
Júlio César Tanos De Lacerda ◽  
Patrícia Carlos Caldeira ◽  
...  

AIDS ◽  
2019 ◽  
Vol 33 (7) ◽  
pp. 1263-1264 ◽  
Author(s):  
Alessandra Latini ◽  
Lavinia Alei ◽  
Renato Covello ◽  
Antonio Cristaudo ◽  
Manuela Colafigli ◽  
...  

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 4970-4970
Author(s):  
Anuradha Avinash Belur ◽  
Arun Kumar Arumugam Raajasekar ◽  
Srikant Nannapaneni ◽  
Thandavababu Chelliah

Abstract Case Description: - A 76 year old lady was diagnosed with Chronic Lymphocytic Leukemia (CLL) with 11 q deletion after she presented with generalized lymphadenopathy and anemia. She was treated with rituximab 375mg/m2 day1 and bendamustine 60mg/m2 on day 1 and day 2 and completed six cycles of treatment. After the sixth cycle she developed multiple itchy, papular lesions with bleeding on both lower extremities. She was evaluated multiple times by vascular surgery and dermatology without a definitive diagnosis. She underwent a biopsy with staining for HHV-8, CD31 and CD34 which was positive confirming the diagnosis of Kaposi sarcoma. ELISA test for HIV was negative. She was started on treatment with Doxorubicin 20 mg/m2every 3 weeks and with 3 cycles there was significant regression of the lesions. Discussion-: We describe a case of CLL which was initially started on treatment with rituximab and bendamustine. She tolerated the treatment well, but a few months later presented with skin lesions which on biopsy was diagnosed as Kaposi sarcoma. It is very uncommon for Kaposi sarcoma to develop in a HIV negative patient. This patient was immunocompromised with recent chemotherapy. Rituximab specifically depletes B cells and leads to impaired T cell mediated immunity. This case illustrates the importance of a high index of suspicion in patients treated with rituximab as it is used for a number of hematologic malignancies like leukemia, lymphoma as well as non-malignant conditions like autoimmune disorders. While infusion reactions and reactivation of hepatitis B are side effects physicians are aware of and cautious of while using rituximab, Kaposi’s Sarcoma remains a less known side effect. Awareness of this possibility is important in physicians prescribing rituximab. Footnotes * Asterisk with author names denotes non-ASH members. Disclosures No relevant conflicts of interest to declare.


1991 ◽  
Vol 30 (2) ◽  
pp. 114-120 ◽  
Author(s):  
Beate Tebbe ◽  
Augusto Mayer-da-Silva ◽  
C. Garbe ◽  
Hans-Joachim Keyserlingk ◽  
Constantin E. Orfanos

2021 ◽  
Vol 9 ◽  
pp. 232470962110174
Author(s):  
Kemnasom Nwanwene ◽  
Noman Ahmed Jang Khan ◽  
Mohamed Alsharedi

Plasmablastic lymphoma (PBL) is a very rare disease and it is usually considered a human immunodeficiency virus (HIV)–related B-cell lymphoma that carries a poor prognosis. It mostly involves the oral cavity, lungs, nasal cavity, gastrointestinal tract, lymph node, and skin. Therapeutic regimens like dose-adjusted etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone (DA-EPOCH) have shown better results in these aggressive lymphomas. We report a rare case of PBL in an HIV-negative patient who presented to the clinic with a complaint of left testicular swelling for 3 months. Ultrasound showed an enlarged left testicle. He underwent a left orchiectomy and the pathology showed PBL with involvement of the spermatic cord margin. Positron emission tomography scan showed hypermetabolic mediastinal and hilar lymph nodes. He was started on DA-EPOCH but showed no response. Accordingly, salvage therapy with bortezomib in addition to ifosfamide carboplatin and etoposide (B-ICE) chemotherapy was initiated with remarkable response. Several other regimens can be used in the refractory setting; however, the evidence is mostly based on retrospective analysis.


2018 ◽  
Vol 66 (6) ◽  
pp. 854 ◽  
Author(s):  
JoseManuel Abalo-Lojo ◽  
Ihab Abdulkader-Nallib ◽  
LauraMartínez Pérez ◽  
Francisco Gonzalez

CHEST Journal ◽  
2021 ◽  
Vol 160 (4) ◽  
pp. A793-A794
Author(s):  
Carlos Vergara-Sanchez ◽  
Christopher Siriphand ◽  
Baher AL Abbasi ◽  
Carlos Dorta ◽  
Katherine Hodgin ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document